Keywords
How to Cite
Abstract
Due to the increasing incidence and prevalence of malignant neoplasms (MN) in Russia, the development of new treatment options is the main component of successful therapy.
One of the newest treatments in this field are the tumor-agnostic therapies, distinguished by their action aimed at targeting MN regardless of localization, if there are specific biomarkers present. Presently, there are tumor-agnostic drugs: entrectinib, larotrectinib and dostarlimab. The majority of clinical trials of these drugs are single-arm trials, which pose several challenges when considering their authorization and funding both in Russia and abroad. Despite this limitation, the discussed drugs are registered or conditionally approved more frequently abroad (USA, Canada, European Union countries, Australia, Japan). Tumor-agnostic drugs are included in foreign clinical guidelines and are funded through public budgets in several countries, despite limited data on clinical effectiveness. This trend is driven by the need to meet the medical requirements for the treatment of life-threatening diseases or those leading to fatal consequences for patients.
References
Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2022:252 [Kaprin AD, Starinsky VV, Shakhzadova AO, editors. Malignant neoplasms in Russia in 2021 (morbidity and mortality). Moscow:P.A. Herzen MNIOI - branch of FGBU «NMRC Radiology» of the Ministry of Health of Russia. 2022:252 (In Russ.)].
Prescribing information ROZLYTREK (entrectinib) capsules, for oral use [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf (accessed: 01.08.2022).
Государственный реестр лекарственных средств: Витракви® [Internet]. Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=f44bb994-1a9c-4c49-ae30-80ca9bdc21b4 (accessed: 01.08.2022).
Prescribing information JEMPERLI (dostarlimab-gxly) injection, for intravenous use [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761174s002lbl.pdf (accessed: 01.08.2022).
Gronchi A, Miah AB, Dei Tos, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Annals of Oncology. 2021;32(11):1348-65. http://dx.doi.org/10.1016/j.annonc.2021.07.006.
Casali PG, Blay JY, Abecassis N, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2022;33(1):20-33. http://dx.doi.org/10.1016/j.annonc.2021.09.005.
Filetti S, Durante C, Hartl DM, et al. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Annals of Oncology. 2022;33(7):674-84. http://dx.doi.org/10.1016/j.annonc.2022.04.009.
Hendriks LE, Kerr KM, Menis J, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology [Internet]. 2023;34(4):339-57. http://dx.doi.org/10.1016/j.annonc.2022.12.009. Available from: https://www.esmo.org/guidelines/guidelines-by-topic/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cance (accessed: 01.08.2022).
Gajjar A, Mahajan A, Abdelbaki M, et al. Pediatric central nervous system cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology [Internet]. J Natl Compr Canc Netw. 2022;20(12):1339-1362. Available from: https://www.nccn.org/professionals/physician_gls/pdf/ped_cns.pdf (accessed: 01.08.2022).
von Mehren M, Kane JM, Riedel RF, et al. NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 1.2022 [Internet]. J Natl Compr Canc Netw. 2022;20(11):1204-14. http://dx.doi.org/10.6004/jnccn.2022.0058. Available from: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (accessed: 01.08.2022).
Swetter SM, Johnson D, Thompson JA, et al. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2023. J Natl Compr Canc Netw [Internet]. 2022;231. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf (accessed: 01.08.2022).
Ettinger DS, Stevenson MM, Ahn D, et al. NCCN Guidelines® Insights: Occult Primary (Cancer of Unknown Primary [CUP]). Version 3.2023 [Internet]. 2022;76. Available from: https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf (accessed: 01.08.2022).
Kumar ShK, Callander NS, Adekola K, et al. Breast Cancer, Version 4.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;107.
Ajani JA, D'Amico TA, Bentrem DJ, et al. Esophageal and Esophagogastric Junction Cancers, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;172 [Internet]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf (accessed: 01.08.2022).
Pfister DG, Spencer Sh, Adkins D, et al. Head and Neck Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;250 [Internet]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (accessed: 01.08.2022).
Benson AB, Venook AP, Al-Hawary MM, et al. Small bowel adenocarcinoma, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;54 [Internet]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/small_bowel.pdf (accessed: 01.08.2022).
Abu-Rustum NR, Yashar CM, Arend R, et al. Uterine Neoplasms, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(8):888-895 [Internet]. https://doi.org/10.6004/jnccn.2021.0038. Available from: https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf (accessed: 01.08.2022).
Ajani JA, D'Amico TA, Bentrem DJ, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(2):167-192 [Internet]. https://doi.org/10.6004/jnccn.2022.0008. Available from: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf (accessed: 01.08.2022).
Go RS, Jacobsen E, Baiocchi R, et al. Histiocytic Neoplasms, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 [Internet]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf (accessed: 01.08.2022).
Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer, Version 3.2022. NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 [Internet]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (accessed: 01.08.2022).
Benson AB, Venook AP, Al-Hawary, et al. Rectal Cancer, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 [Internet]. https://doi.org/10.6004/jnccn.2022.0051. Available from: https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf (accessed: 01.08.2022).
Benson AB, Venook AP, Al-Hawary, et al. Colon Cancer, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 [Internet]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf (accessed: 01.08.2022).
Garcia-Foncillas J, Bokemeyer C, Italiano A, et al. Indirect treatment comparison of Larotrectinib versus Entrectinib in treating patients with TRK gene fusion cancers. Cancers (Basel). 2022;14(7):1793. https://doi.org/10.3390/cancers14071793.
Pollack M, Keating K, Wissinger E, et al. Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies. Curr Med Res Opin. 2021;37(1):59-70. https://doi.org/10.1080/03007995.2020.1847057.
Chu P, Antoniou M, Bhutani MK, et al. Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer. J Comp Eff Res. 2020;9(12):861-876. https://doi.org/10.2217/cer-2020-0063.
Doebele RC, Perez L, Trinh H, et al. Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC. J Comp Eff Res. 2021;10(17):1271-1282. https://doi.org/10.2217/cer-2021-0131.
Krebs MG, Blay JY, Le Tourneau C, et al. Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications. ESMO Open. 2021;6(2):100072. https://doi.org/10.1016/j.esmoop.2021.100072.
Oaknin A, Gilbert L, Tinker AV, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer. 2022;10(1):e003777. https://doi.org/10.1136/jitc-2021-003777.
Patnaik A, Weiss GJ, Rasco DW, et al. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial. Cancer Chemother Pharmacol. 2022;89(1):93-103. https://doi.org/10.1007/s00280-021-04358-3.
Drilon A, Tan DSW, Lassen UN, et al. Efficacy and safety of Larotrectinib in patients with tropomyosin receptor kinase fusion-positive lung cancers. JCO Precis Oncol. 2022;6:e2100418. https://doi.org/10.1200/PO.21.00418.
Hong DS, Bauer TM, Lee JJ, et al. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol. 2019;30(2):325-331. https://doi.org/10.1093/annonc/mdy539.
Laetsch TW, DuBois SG, Mascarenhas L, et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol. 2018;19(5):705-714. https://doi.org/10.1016/S1470-2045(18)30119-0.
Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731-739. https://doi.org/10.1056/NEJMoa1714448.
Le X, Baik C, Bauman J, et al. Larotrectinib Treatment for patients with TRK fusion-positive salivary gland cancers. Oncologist. 2022:oyac080. https://doi.org/10.1093/oncolo/oyac080.
Waguespack SG, Drilon A, Lin JJ, et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol. 2022;186(6):631-643. https://doi.org/10.1530/EJE-21-1259.
Doz F, van Tilburg CM, Geoerger B, et al. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro Oncol. 2022;24(6):997-1007. https://doi.org/10.1093/neuonc/noab274.
Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21(4):531-540. https://doi.org/10.1016/S1470-2045(19)30856-3.
McDermott R, van Tilburg CM, Farago AF, et al. 1955P Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer. Annals of Oncology. 2020;31:S1101-2. http://dx.doi.org/10.1016/j.annonc.2020.08.1347.
Desai AV, Robinson GW, Gauvain K, et al. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022;24(10):1776-1789. https://doi.org/10.1093/neuonc/noac087.
Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21(2):271-282. https://doi.org/10.1016/S1470-2045(19)30691-6.
Dziadziuszko R, Krebs MG, De Braud F, et al. Updated integrated analysis of the efficacy and safety of Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer. J Clin Oncol. 2021;39(11):1253-1263. https://doi.org/10.1200/JCO.20.03025.
Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21(2):261-270. https://doi.org/10.1016/S1470-2045(19)30690-4.
Drilon A, Siena S, Ou SI, et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017;7(4):400-409. https://doi.org/10.1158/2159-8290.CD-16-1237.
Demetri GD, De Braud F, Drilon A, et al. Updated integrated analysis of the efficacy and safety of Entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res. 2022;28(7):1302-1312. https://doi.org/10.1158/1078-0432.CCR-21-3597.
Porta M, ed. A Dictionary of Epidemiology (6 ed). 2014 [Internet]. http://dx.doi.org/10.1093/acref/9780199976720.001.0001. Available from: https://www.oxfordreference.com/view/10.1093/acref/9780199976720.001.0001/acref-9780199976720-e-2306 (accessed: 07.09.2022).
Доступ к новым лекарственным средствам в Европе: технический доклад о политических инициативах и возможностях для сотрудничества и исследований. Всемирная организация здравоохранения. Европейское региональное бюро. 2015;180. [World Health Organization. Regional Office for Europe. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. 2015;180. World Health Organization. Regional Office for Europe. (In Russ.)]. Available from: https://iris.who.int/bitstream/handle/10665/365424/WHO-EURO-2015-3211-42969-67837-rus.pdf?sequence=1&isAllowed=y.
Государственный реестр лекарственных средств [Internet]. [State Register of Medicines (In Russ.)]. Available from: https://grls.rosminzdrav.ru/Default.aspx (accessed: 03.04.2023).
European Medicines Agency [Internet]. Available from: https://www.ema.europa.eu/en (accessed: 03.04.2023).
U.S. Food and Drug Administration. [Internet]. Available from: https://www.fda.gov/ (accessed: 03.04.2023).
Therapeutic Goods Administration (TGA) | Australian Government Department of Health. [Internet]. Available from: https://www.tga.gov.au/ (accessed: 03.04.2023).
Government of Canada. [Internet]. Canada.ca. The official website of the Government of Canada. Available from: https://www.canada.ca/en.html (accessed: 03.04.2023).
Pharmaceuticals and Medical Devices Agency [Internet]. Available from: https://www.pmda.go.jp/english/ (accessed: 03.04.2023).
Institute for Quality and Efficiency in Health Care | IQWiG.de [Internet]. Available from: https://www.iqwig.de/en/ (accessed: 03.04.2023).
Haute Autorité de Santé - Professionnels [Internet]. Available from: https://www.has-sante.fr/ (accessed: 03.04.2023).
Canada’s Drugs and Health Technology Agency. CADTH. [Internet]. Available from: https://www.cadth.ca/ (accessed: 03.04.2023).
The National Institute for Health and Care Excellence. NICE [Internet]. NICE. Available from: https://www.nice.org.uk/ (accessed: 03.04.2023).
Tandvårds- och läkemedelsförmånsverket TLV / The Dental and Pharmaceutical Benefits Agency. [Internet]. TLV. Available from: https://www.tlv.se/in-english.html (accessed: 03.04.2023).
Danish Medicines Council [Internet]. Medicinradet. Available from: https://medicinraadet.dk/om-os/in-english (accessed: 03.04.2023).
Healthcare Improvement Scotland [Internet]. The Scottish Medicines Consortium (SMC). Available from: https://www.scottishmedicines.org.uk/ (accessed: 03.04.2023).
Мельникова Л.С., Федяев Д.В., Герасимова К.В. Инновационные методы лекарственного обеспечения: соглашения о разделении рисков. Злокачественные опухоли. 2016;(4 спецвыпуск 1):99-102 [Melnikova LS, Fedyaev DV, Gerasimova KV. Innovative methods of drug provision: risk-sharing agreements. Malignant tumors. 2016;4(special issue 1):99-102 (In Russ.)].
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. Technology appraisal guidance [TA779]. [Internet]. National Institute for Health and Care Excellence NICE. 2022. Available from: https://www.nice.org.uk/guidance/ta779/chapter/1-Recommendations (accessed: 03.04.2023).
Larotrectinib for treating NTRK fusion-positive solid tumours. Technology appraisal guidance [TA630] [Internet]. National Institute for Health and Care Excellence NICE. 2020. Available from: https://www.nice.org.uk/guidance/ta630 (accessed: 03.04.2023).
Larotrectinib. [Internet]. CADTH. 2020 [updated 2021]. Available from: https://www.cadth.ca/larotrectinib (accessed: 03.04.2023).
Entrectinib for treating NTRK fusion-positive solid tumours. Technology appraisal guidance [TA644] [Internet]. National Institute for Health and Care Excellence NICE. 2020. Available from: https://www.nice.org.uk/guidance/ta644 (accessed: 03.04.2023).
Entrectinib (Rozlytrek). [Internet]. Scottish Medicines Consortium. 2021. Available from: https://www.scottishmedicines.org.uk/medicines-advice/entrectinib-rozlytrek-full-smc2295/ (accessed: 03.04.2023).
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer. Technology appraisal guidance [TA643] [Internet]. National Institute for Health and Care Excellence NICE. 2020. Available from: https://www.nice.org.uk/guidance/ta643/chapter/1-Recommendations (accessed: 03.04.2023).
Entrectinib (Rozlytrek) for ROS1-positive Non-Small Cell Lung Cancer CADTH. 2020 [updated 2021]. Available from: https://www.cadth.ca/entrectinib-rozlytrek-ros1-positive-non-small-cell-lung-cancer (accessed: 03.04.2023).
Entrectinib (Rozlytrek) Scottish Medicines Consortium. 2021. Available from: https://www.scottishmedicines.org.uk/medicines-advice/entrectinib-rozlytrek-full-smc2294/ (accessed: 03.04.2023).
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2023